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Abstract
Colistin sulfate (CS), a polymyxin antibiotic, is used in Canada for the treatment of post-weaning diarrhea in pigs as an al-
ternative to neomycin. The aim of the present study was to evaluate some pharmacokinetics parameters of CS and its effect 
on the evolution of the intestinal Escherichia coli population in pigs challenged with enterotoxigenic E. coli (ETEC): F4. A 
total of 14 weaned piglets were divided into two groups, a non-challenged, treated group (n=7) and a challenged, treated 
group (n=7). Both groups received a single oral dose of CS at 50,000 IU/Kg. Challenge was carried out by oral adminis-
tration of 109 CFU of a hemolytic ETEC: F4 strain resistant to nalidixic acid. Blood samples were taken at 30 min and 1, 2, 
4, 6, 8, 12, 24, 36 and 48 hours post treatment from each pig and CS quantification was performed by LC-MS/MS. In the 
challenged group, severity of diarrhea was monitored and the presence of the ETEC:F4 strain in the feces was enumerated 
using 5% bovine blood agar plates containing nalidixic acid. In both groups, total E. coli counts were carried out using Pet-
rifilm E. coli/Coliform count plates. In both groups, the plasma concentration of CS was below the lower limit of quantifi-
cation (20 ng/ml). Following CS treatment, a decrease in the total E. coli and ETEC: F4 fecal counts were observed at 24 h 
post treatment. The fecal consistency was not affected by CS treatment. 
For the first time, a study of some CS pharmacokinetics parameters with a highly sensitive method showed that CS levels 
are not detectable in systemic circulation following oral administration, and concurrent oral challenge with an ETEC strain 
did not affect CS absorption. A single dose of CS resulted in reduced bacterial counts of the total E. coli and ETEC: F4 
populations in the feces.
Introduction 
Colistin (polymyxin E), a cationic antimicrobial peptide produced by Bacillus polymyxa subsp. Colistinus. This antibiotic 
is used in Canada for the oral therapy of intestinal infections in pigs, particularly those caused by E. coli. Colistin is used 
clinically in the form of its water-soluble colistin sulphate (CS) (Chauvin, Beloeil, Orand, Sanders, & Madec, 2002). In pigs 
receiving therapeutic doses by the oral route, it was found that CS was poorly absorbed, plasma concentrations being less 
than the lower limit of quantitation (0.250 μg/mL) of high-pressure liquid chromatography (Guyonnet et al., 2010). 
The objective of the present study was to develop an analytical technique with high sensitivity for monitoring plasma con-
centrations of CS following oral administration, and to determine the effect of experimental infection with enterotoxigenic 
E. coli (ETEC):F4 (K88) on CS absorption level. And we also determined the effect of an oral dose of colistin (50.000 UI/
kg), on the level of fecal shedding of total E. coli and of ETEC: F4 (K88).
Materials and methods
1. Animals
Fourteen clinically healthy piglets, 21 days of age at the beginning of experimentation, selected for the presence of F4 gene 
by PCR-RLFP were used in this study. Each pig was individually housed in a pen, fed a standard non-medicated ration for 
post-weaning pigs and received water ad libitum. Piglets were weighed at the beginning and end of the experiments. The 
temperature was kept at 24–26°C. Animals were allowed to acclimatize for 2 days before beginning of experiments.
2. Jugular catheterization of pigs and blood sampling
After the 2 days of acclimatization (23 d old), animals were restrained on a V-shaped table, and a catheter was inserted 
over the wire guide in the jugular vein as previously described (Matte, 1999). Blood samples (3mL) from the catheter were 
collected into EDTA tube, from one day after catheter placement (24 d old) until animal’s euthanasia (32 d old). After CS 
oral administration (30 d old), blood samples (3mL) were collected, 30 min and 1, 2, 4, 6, 8, 12, 24, 36 and 48h following 
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CS administration. These samples were used to determine CS plasma concentrations by LC-MS/MS.
3. Experimental infection, antibiotic administration and health status
The challenge strain for experimental infection of pigs, was a nalidixic acid-resistant (Nalr) variant of ETEC F4 strain 
ECL8559 (0149:LT: STa: STb: East1: paa: hemβ: F4), as previously described (Daudelin et al., 2011). At 27 days of age, 7 
pigs were each orally challenged with 5 mL of trypticase soy broth containing 109 CFU of the ETEC F4 challenge strain 
following the administration of 10 mL CaCO3. At 30 days of age, each pig of the two groups of piglets received a single oral 
dose of colistin sulfate (50.000 IU/kg). Clinical examination included observation of fecal consistency, behavioural distur-
bances and presence of cyanosis.  The severity of diarrhea was quantified by using a fecal consistency scoring (0, normal; 1, 
soft feces; 2, mild diarrhea; and 3, severe diarrhea).  
4. Analytical methods
A high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) was used for CS quantification in 
plasma following an oral administration. The HPLC system was a Perkin–Elmer liquid chromatography apparatus (Series 
200, Boston, MA), and the spectrometry system used was an API 2000 QTRAP (AB-Sciex, Concord, Canada). CS was ex-
tracted from pig’s plasma by using a protein precipitation method. The lower limits of quantitation (LLOQ) of the method 
were 20 ng/mL of plasma. Chromatographic separation and the mass spectrometry detection were derived and optimized 
based on (Ma, Wang, Gerber, & Milne, 2008).
5. Microbiological analysis of fecal samples
Faecal samples were collected before challenge and 24, 48, 72, 84, 96, 108, 120 h post challenge. These samples were used to 
examine the presence of the challenge strain ETEC: F4 strain and total E. coli population. A quantity of 10 g of fecal sam-
ples was diluted 10-fold in peptone water and selected dilutions were plated on to Petrifilm E. coli/Coliform count plates, 
and 5% bovine blood agar plates, containing nalidixic acid, for counting of the total E. coli population and the haemolytic 
challenge ETEC F4 strain respectively. The plates were incubated aerobically for 24 h at 37°C.
Results
1. Quantification of plasmatic colistin sulfate concentration 
For the two treated groups 
(infected and not infected), in 
all samples, the plasma con-
centration of CS was less than 
the lower limit of quantitation 
(20ng/mL). In the non-infect-
ed treated group the concen-
tration of CS was greater than 
the limit of detection (LOD) 
after 30 minutes of CS admin-
istration but less than LLOQ 
(Figure 1). However, in the 
non-infected treated group, at 
all sampling times, the con-
centration of CS was less than 
the LOD (figure 2).
Figure 1: LC-MS/MS mass chromatogram of a typical sample from the non-infected 
group at 30 min following CS administration. Plasmatic concentrations of CS were above 
the limit of detection but significantly less than the limit of quantitation (20ng/mL). CS 
was not detected at other time points.
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2. Analysis of Bacterial Shedding and Clinical Scoring of Diarrhea
None of the animals showed 
clinical diarrhea or had to be 
removed from the experiment 
due to illness. However, one 
animal in the infected treat-
ment group was not used due 
to poor feed intake, and was 
consequently removed from 
the experiment. The mean 
number of ETEC: F4 colonies 
recovered from the faeces of 
the 6 experimentally challenged 
treatment pigs is shown in Fig-
ure 3. Experimental challenge 
was performed at 0 hour, and 
treatment with CS was carried 
out at 72h post challenge. The 
administration of a single oral 
dose of CS reduced mean fecal 
ETEC F4 counts during the 
next day following treatment; 
with a maximum effect at 24h 
post-treatment (96h post chal-
lenge). Nevertheless, the mean 
count following treatment was 
not significantly lower than 
the of baseline values (72h post challenge). At 24h post treatment, the fecal ETEC F4 numbers were increased to regain 
baseline values (Figure 3). In both treated groups, that is in challenged and non- challenged animals, total E. coli counts 
demonstrated the same trend of decline as observed for ETEC F4 (i.e maximum effect was observed at 24h post-treatment 
(96h post challenge). The highest mean diarrhea score of the challenged-treated groups was observed at 72h post challenge. 
After CS treatment, there was a tendency for score of diarrhea to decrease, with a maximum effect observed at 48h post 
treatment (120 h post challenge). 
Figure 3: Evolution of the fecal ETEC F4 count (means, and standard deviation). Experimental inoculation was performed 
at 0 hour, and treatment with CS was carried out at 72 hours post challenge. Maximum effect of CS was observed at 24h 
post-treatment (96h post challenge).
Discussion
To the best of our knowledge, non other experimental studies focussing on CS systemic residues in pigs using LC-MS/MS 
as an analytic method. In our study, healthy pigs showed a very small level of systemic CS at 30 minutes after its oral ad-
ministration, and these quantities were lower then the LLOQ. Thus, the absence of CS absorption in healthy pig after oral 
administration despite the use of a sensitive analytic method (LOQ=20 mg/ml), confirms the reports of previous workers 
Figure 2: LC-MS/MS mass chromatogram of a typical sample from the infected group at 
30 min following CS administration. Plasmatic concentrations of CS were less than the 
limit of detection. Furthermore, CS was not detected at other time points.
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who demonstrated that colistin was poorly absorbed and systemic residue levels were usually undetectable (Guyonnet et 
al., 2010). In challenged treated group, CS systemic concentrations were not detected in any of the samples analyzed. These 
results differ from those of studies that have shown that infectious gastroenteritis increases gut permeability, and inflam-
mation appears to act via mast cells, to an increase intestinal permeability (Camilleri, Madsen, Spiller, Greenwood-Van 
Meerveld, & Verne, 2012). In our study, the enterotoxins produced by the ETEC: F4 strain cause secretion of water and 
electrolytes leading to diarrhea with few microscopic lesions (Fairbrother & Gyles, 2012).Thus, diarrhea and the effect of 
enterotoxins may explain the non detection of CS systemic concentration. Our study showed that antibacterial effect of CS 
in bacterial shedding was most important in the 24-h post treatment period, beyond this range, its antimicrobial activity 
being absent. Thereby, one dose per day of CS is ineffective to produce significant dimunition of bacteria counts. 
Conclusion
For the first time, a study of some CS pharmacokinetics parameters with a highly sensitive method showed that CS levels 
are not detectable in the systemic circulation following oral administration in pigs, and concurrent oral challenge with an 
ETEC F4 strain did not affect CS absorption. A single dose of CS resulted in reduced bacterial counts of the total E. coli 
and ETEC: F4 populations in the feces. Further studies are needed to evaluate the effect of CS on E.coli populations and 
potential antimicrobial resistance.
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